In spite of it, the PCA3 test has been useful in clinical trials to reducing the number of biopsies [44] and is a clear example of the importance of lncRNAs as potentially useful molecular markers in PCa but further efforts are needed to include this non-coding transcript as a prognostic biomarker in PCa. The gene discussed is PCA3; the disease is posterior cortical atrophy.